In addition, Ms. Hobson highlights an article that suggests “physicians and consumers should hold the FDA and pharmaceutical manufacturers responsible for maintaining credible information in social media regarding the benefits and risks” of therapies. However, as is sometime the case, most compelling were the comments which offered additional insights into the topic. In particular, I was struck by Jonathan Richman’s (ePharma Summit speaker and author of the Dose of Digital Blog) comment. In it he asks and answers three key questions “First, is it legal (according to the FDA) for pharma to use social media? Second, is the use of social media an effective marketing platform for pharma? And finally, what should pharma be responsible for when it comes to social media?” While his answers are well thought out and offer a great perspective for how the industry should use social media, one question remains, where does the FDA stand on pharma’s role with social media online?
For now, the industry waits for guidance, which may or may not come before the end of the year. In the meantime you can register for the ePharma Summit where not only Jonathan Richman, but Thomas Abrams the director of DDMAC will be on hand to provide what clarity there is to be had by February. Download the brochure for more information. Be sure to mention the code XP1606BLOG to save 10% on your registration.
(Image Courtesy of David Shankbone)




